Immunovant Inc [IMVT] stock is trading at $15.46, up 3.76%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The IMVT shares have gain 2.32% over the last week, with a monthly amount glided 3.83%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Jefferies started tracking the stock with Hold rating on March 03, 2025, and set its price target to $20. On January 03, 2025, downgrade downgraded it’s rating to Peer Perform. Oppenheimer reiterated its recommendation of a Outperform and raised its price target to $53 on October 09, 2024. Oppenheimer started tracking with a Outperform rating for this stock on March 28, 2024, and assigned it a price target of $50. In a note dated March 13, 2024, Goldman initiated an Buy rating and provided a target price of $50 on this stock.
Immunovant Inc [IMVT] stock has fluctuated between $12.72 and $32.10 over the past year. Currently, Wall Street analysts expect the stock to reach $42.83 within the next 12 months. Immunovant Inc [NASDAQ: IMVT] shares were valued at $15.46 at the most recent close of the market. An investor can expect a potential return of 177.04% based on the average IMVT price forecast.
Analyzing the IMVT fundamentals
Gross Profit Margin for this corporation currently stands at -1.34% with Operating Profit Margin at -2944.34%, Pretax Profit Margin comes in at -2784.85%, and Net Profit Margin reading is -2795.64%. To continue investigating profitability, this company’s Return on Assets is posted at -0.68, Equity is -0.84 and Total Capital is -0.77.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 14.99 points at the first support level, and at 14.52 for the second support level. However, for the 1st resistance point, the stock is sitting at 15.94, and for the 2nd resistance point, it is at 16.42.
Ratios To Look Out For
For context, Immunovant Inc’s Current Ratio is 12.32. In addition, the Quick Ratio stands at 12.32 and the Cash Ratio stands at 11.32.
Transactions by insiders
Recent insider trading involved Stout Jay S, Chief Technology Officer, that happened on Jul 23 ’25 when 2805.0 shares were sold. Chief Medical Officer, Geffner Michael completed a deal on Jul 23 ’25 to sell 2385.0 shares. Meanwhile, Chief Medical Officer Geffner Michael sold 1160.0 shares on Jul 09 ’25.
